Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation

BACKGROUND: Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular events in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kühl, Michael, Binner, Christian, Jozwiak, Joanna, Fischer, Julia, Hahn, Jochen, Addas, Alaeldin, Dinov, Boris, Garbade, Jens, Hindricks, Gerhard, Borger, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335020/
https://www.ncbi.nlm.nih.gov/pubmed/30650126
http://dx.doi.org/10.1371/journal.pone.0210373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335020/
https://www.ncbi.nlm.nih.gov/pubmed/30650126
http://dx.doi.org/10.1371/journal.pone.0210373

Ejemplares similares